OncoFreeze AI - Deviceless Motion Management for PET Imaging

OncoFreeze AIDeviceless motion management for PET imaging

OncoFreeze AI - simple, one-button, deviceless correction that reduces scan time6 and setup while enhancing patient comfort

��Գ��ǹ��™¹ AI addresses today’s respiratory motion management challenges. Building on the benefits of OncoFreeze technology, OncoFreeze AI integrates Siemens Healthineers’ proprietary deviceless waveform and anatomical algorithm technology to enable a motion management solution with a simple click of a button.

Features & Benefits

Breathe easy with OncoFreeze AI: simple, one-button, deviceless correction that reduces scan time² and setup while enhancing patient comfort.

With OncoFreeze AI, you combine the power of deviceless waveform generation and Automated Landmarking and Parsing of Human Anatomy (ALPHA) technology to seamlessly create images virtually free of respiratory motion in the same amount of time as a conventional whole-body scan.

PET motion correction is now a reality for every patient and every scan—all with one easy press of a button.

Free of external devices

Faster, more comfortable exams

Extended FOV one-click motion correction

Expert insights

“Now, with OncoFreeze AI, we can offer better-quality scans, independent of indications.”

Dustin Osborne, PhD

Director, Clinical Research
The University of Tennessee Graduate School of Medicine
Knoxville, Tennessee, USA

ALPHA technology

ALPHA technology is a unique, deep learning, artificial intelligence algorithm that detects specific anatomical landmarks. This allows for automatic identification of the zone to be corrected for respiratory motion.

Deviceless waveform

OncoFreeze AI eliminates the need for additional setup of external physiological devices both on the patient and at the scanner and acquires a respiratory waveform that will be used to generate motion-frozen or cine, PET reconstructed images.

Our deviceless waveform is a respiratory signal derived directly from the acquired raw PET list-mode data. The deviceless waveform leverages ��ǷɲѴǳپ��ǲ�™ (continuous bed motion) to always know its location over the body and determine the respiratory signal for axially extended PET acquisitions.

Using a deviceless waveform can have an additional benefit because it can acquire a respiratory waveform even in the case where an external device would fail.

Expert insights

“Using OncoFreeze AI is so much more comfortable for the patients and has an impact— especially for claustrophobic and nervous patients.”

Katie Morris

Deputy Service Lead for Nuclear Medicine and PET/CT
The Royal Marsden NHS Foundation Trust
London, England

Clinical Use

Clinical image review

^{Data courtesy of the Royal Marsden Hospital, London, UK}

OncoFreeze AI helps define lesion edge and volume definition of lung tumor base compared to non-gated PET

Base of lung tumor shows sharper margins with slight decrease in nodule with elimination of respiratory-motion-induced blurring using OncoFreeze AI, as compared to non-gated PET acquisition.

Examination Protocol
Biograph™ Horizon
8.7 mCi (321 MBq) ¹⁸F FDG
CT: 100 kV, 20 ref mAs
PET: 1.1 mm/s head-to-pelvis and 1.3 mm/s extremities FlowMotion continuous bed motion, 180 x 180 matrix

^{Data courtesy on file}

OncoFreeze AI shows similar image quality, motion management, and SUV results compared to respiratory gating device

Lung nodules show sharper visualization and higher SUV from motion management using OncoFreeze AI, as compared to non-gated imaging, due to elimination of respiratory-motion-induced blurring.

Examination protocol
Biograph Vision™³
2.6 mCi (97 MBq) ¹⁸F FDG
CT: 100 kV, 13 ref mAs
PET: 1.3 mm/s FlowMotion continuous bed motion, 440 x 440 matrix

^{Data courtesy of Aarhus University, Aarhus, Denmark}

OncoFreeze AI provides sharp visualization of small lung nodules using deviceless respiratory motion management

Lung tumor in right hilar lung carcinoma shown with sharper visualization using OncoFreeze AI, as compared to non-gated imaging, due to elimination of respiratory-motion-induced blurring.

Examination Protocol
Biograph Vision
6.3 mCi (234 MBq) ¹⁸F FDG
CT: 100 kV, 20 ref mAs
PET: 1.1 mm/s FlowMotion continuous bed motion, 440 x 440 matrix

^{Data courtesy of the Royal Marsden Hospital, London, UK}

OncoFreeze AI helps define lesion edge and volume definition of lung tumor base compared to non-gated PET

^{Data courtesy on file}

OncoFreeze AI shows similar image quality, motion management, and SUV results compared to respiratory gating device

^{Data courtesy of Aarhus University, Aarhus, Denmark}

OncoFreeze AI provides sharp visualization of small lung nodules using deviceless respiratory motion management

^{Data courtesy of the Royal Marsden Hospital, London, UK}

OncoFreeze AI helps define lesion edge and volume definition of lung tumor base compared to non-gated PET

OncoFreeze and OncoFreeze AI

^{Clinical image data courtesy on file}

Optimal flow algorithm: OncoFreeze uses the optimal gate image as a reference and employs an optimal flow algorithm to deblur the static image to match the optimal gate image, using 100% of the information.

OncoFreeze AI benefits from its predecessor, OncoFreeze.
Both solutions support the generation of motion-frozen images without any additional scan time, however OncoFreeze AI acquires a deviceless signal.
Using the optimal gate, the gated image that demonstrates the most quiescent point of the respiratory cycle, OncoFreeze generates a motion frozen image using 100% of the counts from a static image.

Technical Specifications

General Requirements

^{Please Note: Additional technical pre-requisites may apply. Upon receiving your request, your local Siemens representative will clarify whether your system meets the requirements.}

Services & Support

Education & Training

The features herein are not commercially available in all countries. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

Compared to conventional gated scan.

Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer's unique setting. Because there is no "typical" hospital or laboratory and many variables exist (eg, hospital size, samples mix, case mix, level of IT, and/or automation adoption) there can be no guarantee that other customers will achieve the same results.

��ӰԺ